CervoMed Corporation (CRVO): Fair Value Consensus
CervoMed Inc. (CRVO) drug development relies on robust international supply chains for biomaterials utilizing cooling systems. Stringent regulatory requirements and patent complexities create significant barriers to entry for new players in this niche, where the current metric stands at 14.75. The historical price action shown below confirms the brand's status as a recognized expert in the therapy of Lewy body dementia.
Analytical breakdowns for CervoMed Inc (CRVO)
- market price and analyst price targets:
- stock exchange capitalization data:
- book capitalization indicators:
- business debt structure and liquidity details:
- financial results and valuation multiples details:
CRVO - Net Profit|Future Profit CervoMed Inc.|CRVO - P/E Multiple|Projected Price to Earnings Ratio CervoMed, Inc.|CRVO - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation CervoMed Inc|CRVO - Operating profit before deduction of amortization|Earnings per share for the last twelve months CervoMed|CRVO - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months cervomed.com|CRVO - Earnings per share growth in current year|Expected earnings per share growth for next year CervoMed Inc.
Summary company analytics:CRVO cervomed.com
CervoMed Inc. (CRVO) development of dementia drugs is independent of macroeconomic factors; therefore, fundamental value is determined exclusively by the success of clinical trials. The expected consensus share price represents a weighted average analyst target that strips emotion from market quotes, allowing investors to assess the speed at which models adapt to new medical data and the risk of inflated expectations regarding this metric.
Competitors of CervoMed Inc.
Consensus Target biogen.com BIIB|Price Target Chart Neurocrine Biosciences, Inc. NBIX|Fair Value Consensus RGC|AXSM: Consensus Target|ACAD: Price Target Chart|Xenon Pharmaceuticals (XENE) - Price Target Chart|Average Forecast Price vikingtherapeutics.com (VKTX)|Price Target Chart Supernus|Broker Consensus Forecast CPRX (Catalyst Pharma)|Analyst Consensus Forecast DNLI|HRMY - Average Forecast Price|Biohaven Ltd. - Consensus Target|Analyst Consensus Forecast amylyx.com AMLX|TRVI - Price Target Chart|Fair Value Consensus PRAX (Praxis Precision Medicines Inc)|Anavex Corp (AVXL) - Price Target Chart|Average Forecast Price CeriBell EEG (CBLL)|PRTA (Prothena Corporation PLC) - Analyst Consensus Forecast|Consensus Target Alector Therapeutics (ALEC)|Analyst Consensus Forecast ANNX|OMER - Average Forecast Price|Price Target Chart Neurogene Corp NGNE|Fair Value Consensus ACIU|VYGR: Consensus Target|NMRA: Price Target Chart|Scilex (SCLX) - Price Target Chart|Average Forecast Price Tevogen Bio Holdings Inc. (TVGN)|Price Target Chart Alpha Cognition Inc|Consensus Target cogrx.com (CGTX)|Analyst Consensus Forecast IKT|SAVA - Average Forecast Price|Analyst Consensus Forecast ASRT (Assertio)|COYA: Broker Consensus Forecast|VTGN: Consensus Target|Fair Value Consensus OVID (Ovid Therapeutics Inc.)|ABOS: Analyst Consensus Forecast|ATHE - Analyst Median Target|Price Target Chart Clene Inc|Broker Consensus Forecast PEPG (PepGen Corp)|Analyst Consensus Forecast JUNS|Consensus Target Relmada Corp RLMD|Annovis Bio, Inc. - Consensus Target|Analyst Median Target Grace Therapeutics Inc (GRCE)|Firefly Neuroscience - Analyst Consensus Forecast|Klotho Neurosciences Inc (KLTO) - Consensus Target|neurosense-tx.com (NRSN) - Price Target Chart|Reviva Pharmaceuticals, Inc. - Fair Value Consensus|Consensus Target MTVA|Price Target Chart NRXS|Price Target Chart Helius Medical (HSDT)|PASG - Average Forecast Price|Price Target Chart Neuphoria Therapeutics NEUP|NERV: Broker Consensus Forecast|Athira Pharma, Inc. - Analyst Consensus Forecast|Average Forecast Price addextherapeutics.com|ALZN (alzamend.com) - Consensus Target|Cyclerion Therapeutics, Inc. (CYCN) - Analyst Consensus Forecast|Price Target Chart Protagenic Therapeutics Inc.|KTTA: Fair Value Consensus|Price Target Chart Cortigent, Inc. (CRGT)|ATXI - Average Forecast Price|Analyst Consensus Forecast BCLI (BrainStorm Cell Therapeutics)|CARA - Consensus Target|Chromocell Therapeutics Corporation - Analyst Consensus Forecast|Average Forecast Price Eliem Therapeutics|intracellulartherapies.com (ITCI) - Price Target Chart|longboardpharma.com - Fair Value Consensus|Consensus Target MRNS|Price Target Chart NKGN|Price Target Chart NeuroBo (NRBO)|SAGE - Average Forecast Price|Price Target Chart Synaptogenix, Inc. SNPX|TRVN - Consensus Target|Vigil Neuro - Analyst Consensus Forecast|Average Forecast Price Anew Medical Inc.|CERE: Analyst Consensus Forecast
